Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited has overhauled its board leadership as it transitions further into a revenue‑generating commercial phase following its first U.S. FDA approval and successful product launch. Long‑standing chair Jane Bell will step down from the chair role but remain a non‑executive director, with current director Philip Facchina appointed non‑executive chair and Lyn Cobley taking over as chair of the Audit and Risk Committee, while William Burns continues as vice‑chair and chair of the Nomination and Remuneration Committee. The board says the refresh, stemming from a periodic review of its composition and governance structure, is aimed at sustaining a high‑performing, engaged leadership with the right mix of expertise and fresh perspectives, and signals an intention to deepen U.S. commercial expertise over the next year to support the company’s commercialization drive and enhance shareholder value.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global biotechnology company focused on developing allogeneic, off‑the‑shelf cellular medicines for severe and life‑threatening inflammatory conditions. Built on proprietary mesenchymal lineage cell therapy platforms, its lead FDA‑approved product Ryoncil (remestemcel‑L‑rknd) treats steroid‑refractory acute graft versus host disease in pediatric patients, with additional programs targeting adult SR‑aGvHD, biologic‑resistant inflammatory bowel disease, heart failure and chronic low back pain. The company holds an extensive global intellectual property portfolio, operates proprietary large‑scale manufacturing for cryopreserved cell therapies, maintains commercial partnerships in Japan, Europe and China, and is dual‑listed on the ASX and Nasdaq with operations in Australia, the United States and Singapore.
Average Trading Volume: 4,699,673
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.59B
See more data about MSB stock on TipRanks’ Stock Analysis page.